Kaisa Huhtinen
PhD, Adjunct Professor in Cancer Biology
kaisa.huhtinen@utu.fi +358 29 450 2645 +358 50 572 6733 Kiinamyllynkatu 10 Turku : D5038 |
Ovarian cancer; personalized medicine; early diagnostics; prediction; prognosis; biomarker; genomics; drug target; interdicipline research;
- A cancer-specific detection of serum CA125 improves differential diagnosis of epithelial ovarian cancer from benign conditions. (2018)
- Clinical Cancer Research
- A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients (2018)
- Clinical Cancer Research
- CA125 glycoform assay improves the performance of conventional CA125 in the diagnostics of epithelial ovarian cancer (2018)
- International Journal of Gynecological Cancer
- High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment (2018)
- Clinical Cancer Research
- Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis (2018)
- Human Reproduction
- The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer (2018)
- Oncology
- DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer (2017)
- Scientific Reports
- Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells (2017)
- Molecular and Cellular Proteomics
- Uusi lektiini-avusteinen määrityskonsepti parantamaan CA-125-kasvainmerkkiaineen munasarjasyöpäspesifisyyttä (2017)
- Kliin lab
- A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources (2016)
- Clinical Chemistry



